AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05082545 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR-2002 and SHR-1316
Description: Cohort study
Study NCT04874337 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Disaster nursing and management training will be given to students using Jenning's Disaster Nursing and Management Model.
Description: The subjects for the training program were prepared by the researchers by scanning the relevant literature. In particular, the ICN Framework of Disaster Nursing Competencies developed by the International Nurses Association (ICN) and the World Health Organization (WHO), the second is the universal standards that should be fundamental in nursing and midwifery education (Global Standards for the Initial Education of Professional Nurses and Midwives). The training program was conducted both theoretically and practically. The theoretical section is based on Jenning's disaster nursing management model. Investigator is a First and Emergency Aid instructor. In addition, support was received from an experienced psychologist and AFAD trainers who provided support to the victims of the Izmir earthquake during the training process. In this context, an 8-module training program was created.
Study NCT05111366 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TQB2450 injection
Description: TQB2450 is an injection in the form of 1200mg, ivgtt, q3W.
Study NCT05111366 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anlotinib hydrochloride capsules
Description: Anlotinib Hydrochloride is a capsule in the form of 8 mg,10 mg, and 12 mg, orally, once daily, 2 weeks on/1 week off.
Study NCT04748705 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IMC-1
Description: Patients will take 1 tablet twice daily, each morning and evening, of randomly assigned study drug orally starting on Day 1 through study duration.
Study NCT04748705 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo BID Tablet
Description: Patients will take 1 tablet twice daily, each morning and evening, of randomly assigned study drug orally starting on Day 1 through study duration.
Study NCT06291831 — intervention group
Intervention type: OTHER
Intervention: Controls
Description: Patients who do not receive Nirmatrevir/ritonavir (Paxlovid)
Study NCT05014945 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: (atelocollagen group)
Description: Epidural nerve block and atelocollagen injection into the multifidus muscle were performed sequentially. The target level is determined by the clinician by combining the pre-MRI and the patient's symptoms. All procedures are performed under the guidance of fluroscopy. For epidural nerve block, use 10cc of 0.9% normal saline mixed with 3000IU of hyaluronidase to be injected. After the epidural nerve block, a solution of 1 mL of atelocollagen mixed with 1 mL of 1% lidocaine is injected into the multifidus muscle to complete the entire procedure.
Study NCT05984225 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Online learning
Description: The students performed a 10-week Online Learning (OL) program based on Professional Ethics. The program included:~1. Synchronous learning (1 session/week, 1 hour each).~2. Asynchronous learning: i) OL classes were recorded; ii) Moodle platform: for read breaking news, upload tasks or solve any doubt they may have through discussion forums; iii) An OL specific syllabus that consisted of five themes from the ethics knowledge; iv) An OL glossary, including the concept, explanation of the concept, and source; v) Bullet-point videos highlighting the most important issues of each theme; vi) Podcasts about Professional Ethics, Ethics in physiotherapy; vii) Links to websites; viii) Gamification using mobile Apps regarding ethical decision-making, healthcare, and Ethics or Professional Ethics, as well as an OL crossword; ix) OL activities were created and personalized comments about the activities were reported by the teachers to give feedback to the students.
Study NCT06087965 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fingolimod
Description: 0.5mg/day oral fingolimod over a course of 3 consecutive days
Study NCT04590495 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 300 mg Cannabidiol (CBD) oil
Description: Participant will either be given a 300mg dosage of CBD oil. After consumption of the study drug, the participant will wait for 120 minutes to allow for digestion and for CBD to begin taking effect. Next, individuals will undergo a driving simulation and all participants will drive the same course. The simulator presents the individual with real life driving scenarios and is equipped with screens, a steering wheel, signals, and pedals. The participant will be instructed to drive the course for 25-35 minutes. They will be instructed to follow normal driving rules. The simulation will include highway, suburban, rural, and urban driving scenarios which will incorporate turns, changes in speed, and avoidance of cars/pedestrians.
Study NCT04590495 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participant will either be given a placebo . After consumption of the study drug, the participant will wait for 120 minutes to allow for digestion and for CBD to begin taking effect. Next, individuals will undergo a driving simulation and all participants will drive the same course. The simulator presents the individual with real life driving scenarios and is equipped with screens, a steering wheel, signals, and pedals. The participant will be instructed to drive the course for 25-35 minutes. They will be instructed to follow normal driving rules. The simulation will include highway, suburban, rural, and urban driving scenarios which will incorporate turns, changes in speed, and avoidance of cars/pedestrians.
Study NCT06331793 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Active AlgoCare
Description: Device that emits Pulsed Electromagnetic Fields
Study NCT06331793 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Non-active AlgoCare
Description: Device that doesn't emit Pulsed Electromagnetic Fields
Study NCT05689645 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: F573 for injection
Description: The first 16 patients with liver injury were given doses of 0.5, 1.0 and 2.0 mg/kg,2 mL,intramuscular injection (IM),once a day for 7 daysand. the subsequent 9 patients with CHB were given doses of 2 mL intramuscular injection (IM), once a day for 7 days, according to the results of the efficacy and safety trials of the first 16 patients. The dose of the second stage was determined according to the results of the efficacy and safety trials in the first stage. The dose volume was 2 mL, and was administered intramuscular injection (IM) once a day for 14 days. The dosage of the third stage was determined according to the results of the first and second stage efficacy and safety trials. The dosage volume was 2 mL and intramuscular injection (IM) was administered once a day for 28 consecutive days. The dosage of the above three stages of administration was calculated according to the weight of the most recent visit
Study NCT05689645 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sterilizing water for injection
Description: The composition of this product is water for injection, and the dosage volume is 2mL for intramuscular injection.~Medication course: The first stages were administered once a day for 7 days and second stages were administered once a day for 14 days. The third stage was administered once a day for 28 days.
Study NCT05281809 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chimeric Antigen Receptor (CAR) T-Cell Product (Autologous)
Description: This protocol describes the use of an automated cell processor and culture system, the CliniMACS Prodigy device sold by Miltenyi Biotec, for the local manufacture of CAR T-cells targeting the CD19 antigen. The manufacturing process will use a lentiviral vector (CAR19) provided by Lentigen, a wholly owned subsidiary of Miltenyi Biotec, to transfect T-cells collected from eligible patients. Live cells will be harvested by the device after culture and infused intravenously to the patient from whom the cells were originally obtained.
Study NCT06296303 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pulsed electromagnetic therapy
Description: Pulsed etromagnetic therapy (1000 gauss) on sciatic nerve in gluteal fold. ( 30 min )
Study NCT06296303 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ultrasound phonophoresis
Description: Phonophoresis using dexamethasone and topical diclofenac sodium gel on sciatic nerve in subgluteal fold and mid thigh
Study NCT06296303 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional physical therapy
Description: Conventional physical therapy consisting of~1. IF current on lumbar spine. (15 min )~2. Hotpack on lumbar spine . (15 min )~3. Neurodynamic mobilization .~4. Mobilization and manipulation for lumbar spine.~5. Exercises
Study NCT06296303 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Conventional physical therapy
Description: Conventional physical therapy consisting of~1. IF current on lumbar spine. (15 min )~2. Hotpack on lumbar spine . (15 min )~3. Neurodynamic mobilization .~4. Mobilization and manipulation for lumbar spine.~5. Exercises
Study NCT05982535 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Easy Dew MD Regen Cream
Description: The subject applies the provided medical device twice a day (morning and evening) to areas with symptoms of dry skin so that it can be absorbed well.
Study NCT05982535 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Easy Dew MD Regen Cream
Description: The subject applies the provided medical device twice a day (morning and evening) to areas with symptoms of dry skin so that it can be absorbed well.
Study NCT04862507 — intervention group
Intervention type: OTHER
Intervention: Telephone call on day 90
Description: telephone call on day 90 to assess the primary outcome (mRs 90)
Study NCT06209099 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Nonoperative Management (NOM)
Description: Drug: Oxaliplatin (OXA) Drug: Capecitabine (CAPE) Radiation: intensity modulated radiotherapy (IMRT) Behavioral: DRE-Endoscopy-MRI-CEA Procedure: Nonoperative Management (NOM)
Study NCT06209099 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Local Excision (LE)
Description: Drug: Oxaliplatin (OXA) Drug: Capecitabine (CAPE) Radiation: intensity modulated radiotherapy (IMRT) Behavioral: DRE-Endoscopy-MRI-CEA Procedure: Local Excision (LE)
Study NCT04862507 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Quantification of lesion water uptake by CT densitometry
Description: Retrospective quantification of lesion water uptake by CT densitometry in admission and follow-up imaging
Study NCT05088122 — intervention group
Intervention type: OTHER
Intervention: no intervention
Description: no intervention, not applicable
Study NCT06209099 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Total Mesorectal Excision (TME)
Description: Drug: Oxaliplatin (OXA) Drug: Capecitabine (CAPE) Radiation: intensity modulated radiotherapy (IMRT) Behavioral: DRE-Endoscopy-MRI-CEA Procedure: Total Mesorectal Excision (TME)
Study NCT04790682 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: assessment of the predictive value of ctDNA level of the prominent mutant allele variation between baseline and week 6, on response to treatment according to RECIST 1.1 criteria.
Description: * At pre-screening NGS analysis on tumor tissue (slides). Only patients with at least 1 mutation at NGS on the tumor tissue will ultimately be enrolled in the main study, to have the possibility to follow the mutation using ctDNA.~* Main study will be initiated after results of the NGS and before initiation of pembrolizumab. Blood specimens will be taken with EDTA tubes or streck tubes at the time of puncture for pembrolizumab infusion at baseline before starting treatment, at 3 weeks, 6 weeks and then every 6 weeks (30 ml at Baseline then 20 ml of blood). Blood immunomonitoring will be done before starting the treatment, at 6 weeks and at 18 Week. An additional measurement will be performed if treatment is stopped before the end of the study (18 ml of blood).~* Optional blood samples will be realized to analyse the degree of activity of the plasmatic lymphocytes before starting the treatment and at 6 weeks and (18 ml of blood).
Study NCT05712954 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: music group
Description: music
Study NCT05712954 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: video group
Description: video
Study NCT05150717 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [14C]-Jaktinib
Description: Subjects will receive single dose of orally \[14C\]-Jaktinib on Day 1.
Study NCT05731518 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SC0245
Description: SC0245 Quaque Die(QD) administered with a 3-day on and 4-day off schedule in Day 1 Day8 and Day 15 of each cycle. One cycle is consisted of 28 days.
Study NCT05947656 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NaviFUS System
Description: NaviFUS System (Neuronavigation-Guided Focused Ultrasound System) is a new non-invasive device, which uses the neuronavigation principle to guide focused ultrasound (FUS) energy precisely delivering through the skull to selected brain tissues without surgery in real-time. In this clinical study, the NaviFUS System is intended to deliver low intensity FUS to generate neuromodulation effects on a predetermined treatment region (one or both of the hippocampi which are associated with seizure), for the treatment for drug-resistant temporal lobe epilepsy (TLE).
Study NCT06316076 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CD19-CAR-DNT cells
Description: Lentiviral vector-transduced DNT cells to express anti-CD19 CAR. Prior to cellular infusion, each patient received cyclophosphamide and fludarabine lymphodepleting chemotherapy.
Study NCT05498467 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Anakinra
Description: 100 mg Anakinra injections s.c.
Study NCT05498467 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sodium Chloride 9mg/ml Injection
Description: 9 mg Sodium Chloride injections s.c.
Study NCT05731518 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan
Description: Irinotecan 80mg/m\^2 via IV administered for every 4 weeks (fixed dosing) in Day 1 Day8 and Day 15 of each cycle. One cycle is consisted of 28 days.
Study NCT05357508 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intervention brochure
Description: Provide participants with information about their personalized risk for colorectal cancer and appropriate screening recommendations to facilitate their screening option choice.
Study NCT05357508 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Control brochure
Description: Provide participants with general information about options for colorectal cancer screening.
Study NCT06508515 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Unadapted Research Units in Behavioral Intervention (RUBI) implementation strategy
Description: The unadapted RUBI IS involves weekly, one hour educational meetings where sessions involve discussion of homework from the week prior (5 minutes), didactic instruction on targeted behavioral strategies (40 minutes), coaching and consultation around the newly learned strategy (10 minutes), and fidelity review, where RUBI implementation is observed (5 minutes). Finally, Attend\| Behavior® is a HIPAA-compliant mobile application support that is designed to support RUBI delivery and implementation.
Study NCT06508515 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: RUBI in Educational Settings (RUBIES)-Team
Description: RUBIES is an 8-module intervention that provides educators a range of skills to support the building of a behavioral management toolbox to be used, as needed, with autistic children and disruptive behavior. The program emphasizes: 1) tailoring the intervention to the specific child; 2) identifying behavioral function instead of topography as a means to inform behavioral strategy choice; 3) decreasing behavioral excess as well as increasing appropriate behaviors; and 4) using positive behavioral supports, such as antecedent management (e.g., use of visual supports), reinforcement, and functional communication strategies to modify behaviors. All educators will receive RUBIES training across 24 weeks via Zoom.
Study NCT05152576 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OnabotulinumtoxinA X
Description: Intramuscular Injection
Study NCT05152576 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Intramuscular Injection
Study NCT06060054 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Device measurements
Description: Overnight device measurements
Study NCT05271760 — intervention group
Intervention type: PROCEDURE
Intervention: Single-shot spinal analgesia
Description: The intrathecal medication included 1ml of 0.5% heavy bupivacaine (5 mg) and 25 μg fentanyl, CSF barbotage will do to reach a total volume of 2 ml
Study NCT05271760 — intervention group
Intervention type: PROCEDURE
Intervention: Continuous epidural analgesia
Description: Epidural analgesia is performed using a 16-gauge Tuohy epidural needle using a loss-of-resistance- to-saline technique, upon feeling the loss of resistance an epidural catheter will be introduced cranially through the needle for 5 cm in the L3-L4 epidural space, after negative aspiration for blood or spinal fluid a test dose of 3 ml lidocaine 1.5% with epinephrine 1:200000 will be given via inserted catheter, 10 ml of 0.125 % bupivacaine and 2ug/ml fentanyl will be injected as a loading dose then the solution will infuse in a rate of 6 -14 ml/h.
Study NCT05271760 — intervention group
Intervention type: PROCEDURE
Intervention: Combined spinal-epidural analgesia
Description: Epidural analgesia is performed using a combined spinal-epidural set. using a loss-of-resistance- to-saline technique, upon feeling the loss of resistance, once epidural space will be detected, 27 G Whitacre spinal needle inserted through Touhy epidural needle, intrathecal injection of 1ml of 0.5% heavy bupivacaine (5 mg) and 25 μg fentanyl, CSF barbotage will do to reach a total volume of 2 ml. Then an epidural catheter will be introduced cranially through the needle for 5 cm in the L3-L4 epidural space, after negative aspiration for blood or spinal fluid.~10 ml of 0.125 % bupivacaine and 2ug/ml fentanyl will be injected as a loading dose then the solution will infuse at a rate of 6 -14 ml/h if needed.
Study NCT01002183 — intervention group
Intervention type: DRUG
Group type: NO_INTERVENTION
Intervention: Fosmidomycin
Description: 450 mg capsules, every 12 hrs for 3 days
Study NCT04771702 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Edmon
Description: Exhaled air will be analyzed for propofol
Study NCT05062486 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Resveratrol, Quercetin, Curcumin (RQC)
Description: 100 mg resveratrol, 120 mg quercetin, 1000 mg curcumin BID
Study NCT05062486 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Curcumin
Description: 1000 mg curcumin BID
Study NCT04959162 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: E-learning
Description: Development of theoretical knowledge using a E-learning platform before attending a hands-on course in musculoskeletal ultrasound
Study NCT04959162 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional preparation
Description: Attending a hands-on course in musculoskeletal ultrasound with no preparation before course start
Study NCT05026060 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Imaging
Description: 4-minutes eASL sequence without injection of contrast product added to each of the clinical MRs with standard ASL sequences performed for the care of the patient for 3 years.
Study NCT04757974 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fostemsavir 600 mg
Description: Fostemsavir tablets will be administered via oral route.
Study NCT06231979 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Description: 1 μg/kg Dexmedetomidine per side in erector spinae block
Study NCT06231979 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivacain
Description: 18 mL of bupivacaine 0.25 % per side in erector spinae block
Study NCT06231979 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Normal saline
Description: 2 ml normal saline 0.9% per side in erector spinae block
Study NCT05458804 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: VR training
Description: A musical game called Beat Saber was used to conduct training sessions. The participant's task was to cut through the blocks of various colors in his direction to the rhythm of music, using two virtual swords. The swords were controlled by the player with controllers of different colors. Blocks had to be cut with a sword whose color matches the block and in the right direction which is indicated by an arrow on the block. The training session consisted of 4 music tracks with different paces and intensities of objects. In addition, during the song, the participant had to avoid objects-objects that randomly appeared in the game scenario - forcing the whole body to move.
Study NCT05238545 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: gluten-free diet
Description: Diet excluding foods containing gluten.
Study NCT06026878 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gemcitabine,nimotuzumab, toripalimab
Description: same as before
Study NCT06026878 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: gemcitabine, cisplatin
Description: same as before
Study NCT05545683 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VLA 2001
Description: VLA2001 is a highly purified whole virus, inactivated, adjuvanted vaccine, using the manufacturing platform of Valneva's encephalitis (JE) vaccine
Study NCT04757974 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fostemsavir 200 mg
Description: Fostemsavir tablets will be administered via oral route.